Synergistic Cholestatic Disease Management System
Legal Citation
Summary of the Inventive Concept
A novel system integrating elafibranor treatment with AI, IoT, blockchain, and new materials to provide personalized, data-driven management of cholestatic diseases
Background and Problem Solved
The original patent addressed the treatment of cholestatic diseases, specifically PBC and PSC, with elafibranor. However, it did not provide a comprehensive solution for monitoring, predicting, and adapting to disease progression. The new inventive concept addresses this limitation by incorporating distinct technologies to create a more powerful system
Detailed Description of the Inventive Concept
The system comprises a wearable device for tracking patient biomarkers, an AI-powered analytics module for predicting disease progression, and a personalized treatment planner integrating elafibranor administration with lifestyle recommendations. Additionally, the system incorporates machine learning algorithms for optimizing elafibranor treatment, a blockchain-based platform for secure data management, a smart pillbox system for ensuring patient adherence, and a novel biomaterial composition for oral delivery of elafibranor
Novelty and Inventive Step
The new claims introduce a synergistic combination of distinct technologies, providing a holistic approach to cholestatic disease management. The inventive step lies in the integration of these technologies to create a more effective and personalized treatment system
Alternative Embodiments and Variations
Alternative embodiments could include different AI algorithms, various wearable devices, or alternative blockchain platforms. Variations could also include integrating the system with electronic health records or telemedicine platforms
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, digital health, and disease management
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/192 |
| A | A61 | A61K45/06 |
| A | A61 | A61P37/06 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical technology and pharmaceutical treatment systems, specifically focused on cholestatic disease management, involving pharmacological interventions, medical device integration, and personalized treatment technologies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with expertise in pharmaceutical sciences, medical device engineering, data analytics, and clinical treatment protocols, possessing advanced knowledge of drug delivery systems, patient monitoring technologies, and computational healthcare solutions
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies with existing pharmaceutical treatments represents a predictable and logical extension of current medical management strategies. The combination of elafibranor treatment with AI-driven analytics, IoT monitoring, and advanced drug delivery systems follows established trends in personalized medicine. The technical variations disclosed represent incremental improvements using known technological approaches to enhance treatment effectiveness and patient outcomes.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,523 |
|---|---|
| Title | Methods of treatment of cholestatic diseases |
| Assignee(s) | Genfit |